Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax Inc (NVAX) is a clinical-stage biotechnology company pioneering vaccine development through recombinant nanoparticle technology and its proprietary Matrix-M adjuvant. This dedicated news hub provides investors and industry observers with timely updates on corporate developments, clinical trial progress, and regulatory milestones.
Our curated collection of Novavax news ensures access to official press releases, financial disclosures, and strategic partnership announcements. Users will find updates spanning vaccine candidate advancements, manufacturing expansions, and peer-reviewed research findings. Key content areas include quarterly earnings reports, FDA regulatory submissions, and global health collaborations.
Bookmark this page for streamlined tracking of Novavax's progress in addressing infectious diseases like COVID-19, influenza, and RSV. The resource is regularly updated to serve as your primary source for verified information about NVAX's scientific innovations and market positioning.
Novavax (Nasdaq: NVAX) announced a significant agreement with the European Commission for up to 200 million doses of its COVID-19 vaccine, NVX-CoV2373, including an initial purchase of 100 million doses. Deliveries are set to commence post-approval from the European Medicines Agency, expected in Q3 2021. Clinical trials showed NVX-CoV2373's efficacy at 90.4% against overall infection and 100% against severe disease. This partnership aims to bolster vaccine options for Europe and globally amid the ongoing pandemic.
Novavax, Inc. (Nasdaq: NVAX) will announce its second quarter 2021 financial results and operational highlights on August 5, 2021, at 4:30 p.m. ET. The announcement will be followed by a conference call, accessible at www.novavax.com/events. Notably, Novavax is conducting late-stage clinical trials for its COVID-19 vaccine, NVX-CoV2373, and has achieved positive results with its NanoFlu™ vaccine for influenza, which met all primary objectives in its Phase 3 trial.
Novavax, Inc. (Nasdaq: NVAX) released the final analysis of its pivotal Phase 3 clinical trial for the COVID-19 vaccine NVX-CoV2373, published in the New England Journal of Medicine. The trial demonstrated an overall efficacy of 89.7% against all strains and 96.4% against non-B.1.1.7 variants. Conducted in the UK with over 15,000 participants, the study confirmed the vaccine's strong safety and efficacy profile, highlighting its potential in combating COVID-19. The results align closely with previous trial data, reinforcing confidence in NVX-CoV2373's role in the pandemic response.
Novavax, Inc. (Nasdaq: NVAX) announced participation in the 2nd Annual CybeRx Series: Vaccine Forum on June 22, 2021. The fireside chat will feature discussions around NVX-CoV2373, Novavax's recombinant nanoparticle protein-based COVID-19 vaccine. The event will be moderated by Geoffrey Porges, with Novavax leaders Gregory M. Glenn and John J. Trizzino participating. This forum highlights Novavax's innovative approach to vaccine development, particularly in combating serious infectious diseases.
Novavax, a biotechnology company, announced that Gregory M. Glenn, M.D., its President of Research and Development, will participate in a session at the National Vaccine Advisory Committee meeting on June 17, 2021. The discussion will focus on Novavax' COVID-19 vaccine candidate, NVX-CoV2373. The session is scheduled from 3:15 p.m. to 4:15 p.m. ET, titled Experiences in the Field: COVID-19 Vaccine Authorization and Beyond. Novavax is advancing its vaccine to combat SARS-CoV-2, aiming to enhance global health through innovative vaccines.
Novavax (Nasdaq: NVAX) announced promising results from its first co-administration study of its COVID-19 vaccine candidate, NVX-CoV2373, alongside an influenza vaccine. Conducted in the UK with 431 volunteers, the study showed vaccine efficacy rates of 87.5% for the co-administered group and 89.8% for the main study. The findings suggest that simultaneous vaccination could enhance public health efforts by reducing healthcare visits. The vaccine demonstrated a favorable safety profile, with mild reactogenicity and preserved immunogenicity for the influenza vaccine.
Novavax, Inc. (Nasdaq: NVAX) reported promising results from its PREVENT-19 Phase 3 trial for the COVID-19 vaccine NVX-CoV2373. The vaccine demonstrated 100% efficacy against moderate and severe disease and an overall efficacy of 90.4%, achieving its primary endpoint. The study involved 29,960 participants across the U.S. and Mexico. Novavax plans to apply for regulatory approvals in Q3 2021 and expects to manufacture 100 million doses per month by the end of Q3. The vaccine showed strong efficacy against Variants of Interest and Concern.
Novavax, Inc. (Nasdaq: NVAX) announced promising data on its COVID-19 vaccine candidate, NVX-CoV2373, against the SARS-CoV-2 Beta variant. Recent studies show strong immunogenicity and protection against both Alpha and Beta variants. Results indicated that booster doses of a variant-directed vaccine could enhance immune responses significantly. Notably, mice and baboons demonstrated robust antibody responses, and human trials have shown neutralizing capacity against variants. Further clinical testing is expected to commence in Fall 2021, indicating the potential for broader vaccine protection.
Novavax (NASDAQ: NVAX) will host Maryland Governor Larry Hogan on June 10, 2021, at its future Vaccines Innovation Campus in Gaithersburg. The event at 9:30 AM ET will include a tour and press briefing led by CEO Stanley C. Erck and Greg Glenn, M.D. This follows approval by Gaithersburg's city officials for expansion, enhancing R&D and manufacturing capabilities. Novavax aims to grow its presence in Maryland’s biotech sector while advancing its COVID-19 vaccine and other projects.
Novavax (Nasdaq: NVAX) has announced that CEO Stanley C. Erck will take part in a panel discussion at the BIO International Convention 2021 on June 14. The event, hosted by the Biotechnology Innovation Organization, is scheduled for June 10-11 and June 14-18. The panel will focus on global pandemic preparedness, featuring discussions about Novavax's COVID-19 vaccine candidate, NVX-CoV2373. This protein-based vaccine is designed to combat SARS-CoV-2 and is currently under evaluation in multiple clinical trials.
